For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Teneobio, Inc.

USPTO Granted Patents = 15

EPO Patents = 2

Forward Citations = 11

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Nathan D Trinklein (14 out of 23 patents)

Katherine Harris (12 out of 17 patents)

Shelley Force Aldred (9 out of 18 patents)

4. Wim Van Schooten (9 out of 19 patents)

5. Kevin Dang (3 out of 3 patents)

6. Duy Pham (2 out of 5 patents)

7. Udaya Rangaswamy (2 out of 2 patents)

8. Harbani Kaur Malik Chaudhry (2 out of 3 patents)

9. Brian Avanzino (2 out of 2 patents)

10. Karen Chang (2 out of 2 patents)

11. Nicole Allen (2 out of 2 patents)

12. Ute Schellenberger (1 out of 3 patents)

13. Omid Vafa (1 out of 3 patents)

14. Starlynn Clarke (1 out of 3 patents)

15. James Noble Kochenderfer (1 out of 30 patents)

15 patents: Sort by Forward Citations

1. 12747298 - MULTI-SPECIFIC ANTIBODIES BINDING TO BCMA (2026-09-29),

2. 12735503 - ANTI-MUC1-C ANTIBODIES AND CAR-T STRUCTURES (2026-09-15),

3. 12709644 - ANTI-CD20 ANTIBODIES AND CAR-T STRUCTURES (2026-08-18),

4. 12590163 - AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE (2026-03-31),

5. 12570717 - ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS (2026-03-10),

6. 12495776 - TRANSGENIC NON-HUMAN ANIMALS PRODUCING MODIFIED HEAVY CHAIN-ONLY ANTIBODIES (2025-12-16),

7. 12371505 - Anti-BCMA heavy chain-only antibodies (2025-07-29),

8. 12180298 - Heavy chain antibodies binding to PSMA (2024-12-31),

9. 11970540 - Anti-BCMA heavy chain-only antibodies (2024-04-30),

10. 11905326 - Multispecific heavy chain antibodies binding to CD22 and CD3 (2024-02-20),

11. 11884735 - Agonistic anti-IL-2R antibodies and methods of use (2024-01-30),

12. 11873336 - Heavy chain antibodies binding to CD22 (2024-01-16),

13. 11613572 - CD3 binding antibodies (2023-03-28),

14. 11505606 - CD3 binding antibodies (2022-11-22),

15. 11434299 - Anti-BCMA heavy chain-only antibodies (2022-09-06),

Teneobio, Inc. is a biotechnology company based in Newark, California, specializing in the development of innovative therapeutic antibodies. The organization focuses on creating next-generation antibody formats that enhance the efficacy and safety of treatments for various diseases, including cancer and autoimmune disorders. Teneobio leverages its proprietary technology platform to design and optimize these biologics, aiming to address unmet medical needs and improve patient outcomes through advanced therapeutic solutions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

15 Patents

#29 in Newark, CA

#5,022 in California

#21,034 in US

#39,881 in the World

Newark, CA, United States of America

Teneobio, Inc.

Forward Citations = 11

30 inventors:

Nathan D Trinklein (14 out of 23 patents)

Katherine Harris (12 out of 17 patents)

Shelley Force Aldred (9 out of 18 patents)

4. Wim Van Schooten (9 out of 19 patents)

5. Kevin Dang (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…